Amgen, the world’s largest biotech company, said today it has applied for FDA clearance to sell denosumab for women with osteoporosis and to treat and prevent bone loss for certain patients with prostate or breast cancer. The drug showed in clinical trials it can lower the risk of spinal fractures, a finding that analysts say could propel it to more than $2 billion in annual sales. Amgen (NASDAQ: [[ticker:AMGN]]) has research centers in Seattle and Cambridge, MA.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
